Huidu (Shanghai) Medical Sciences

Huidu (Shanghai) Medical Sciences, operating as the Chinese arm of Predicine, is a molecular diagnostics company specializing in precision oncology. The company leverages its proprietary liquid biopsy and next-generation sequencing (NGS) platforms to provide genomic profiling for cancer patients, clinical trial enrichment for pharmaceutical partners, and early cancer detection. Their core offerings include the PredicineCARE and PredicineATLAS assays, which detect genetic alterations in blood and urine samples. Huidu Medical collaborates extensively with global biopharmaceutical companies to support drug development and companion diagnostic (CDx) strategies. The company maintains CLIA-certified and CAP-accredited laboratories to ensure high-quality clinical testing services.